你的位置: 首页 >  制药资讯 >  文章正文

2021年第40届欧洲放射肿瘤学会大会/年会(ESTRO2021)

时间: 2020年08月01日 21:19 | 作者:朗依制药 | 来源: 医药资讯| 阅读: 129次

           
   

◆ 会议时间:2021年5月7日至11日
◆ 会议地点:西班牙 马德里/Madrid, Spain


◆ 会议简介:

2021年第40届欧洲放射治疗与肿瘤学会(ESTRO)年会/大会将于2021年5月7日至11日在西班牙马德里举行,ESTRO年会是欧洲最大的放射肿瘤学会议与展览会。

欧洲放射治疗与肿瘤学学会(ESTRO)成立于1980年,是一个非营利性科学组织。ESTRO在欧洲内外拥有超过7600名成员,其中包括放射肿瘤学家、医学物理学家、放射生物学家和RTT(放射治疗师)以及肿瘤学界的其他相关专业人员。ESTRO致力于通过代表大会、特别会议、教育课程和出版物等,不断促进放射治疗学在多种肿瘤临床治疗中的应用,以改善对患者的护理。

ESTRO通过组织放射肿瘤学和癌症多学科治疗各方面的会议使其在国际上享有盛誉,其中既有数千名代表参与的大型会议,亦有高度专业化的团体会议。同时,ESTRO也多次与其他国际知名学术组织合作,使会议成为一个能够充分交流知识和经验的平台。 — —领域国际医学会议网翻译整理,未经许可禁止复制摘录转载本站任何内容。

以下为2020年会议信息

重要日期:
Abstract submission: 23 October 2019
Early registration: 14 January 2020
Late abstract submission: 15 January 2020
Late registration: 12 November 2020


邀请信:

It is my privilege and great pleasure to invite you to ESTRO 39 that will take place 3-7 April 2020 in Vienna, Austria. 

We are pleased that this year the World Congress of Brachytherapy will take place adjacent to ESTRO 39 from 2-4 April 2019 in the same venue as ESTRO 39.

ESTRO is a multi-professional society focusing on radiation oncology as a core component of high- quality, multidisciplinary cancer treatment, in partnership with other oncology societies.

Radiotherapy is a team effort, delivered by an interdisciplinary team consisting of radiation oncologists, clinical oncologists, medical physicists, radiobiologists, radiation therapists (RTTs) and nurses. The Society wishes to engage them all in their congress, together and in discussion with other oncology specialists.

In line with the ESTRO vision 2030 ‘Radiation Oncology. Optimal Health for all, together’, ESTRO 39 will convey the theme ‘Translating research and partnership into optimal health’.

Advances in technologies and methodologies of radiation oncology continue to evolve very rapidly. However, these innovations will only truly provide impact when the new findings can be translated into clinical applications that will result in optimal benefit for each individual patient in daily practice. Radiation oncology professionals should not try to achieve such optimal outcome by themselves but in dialogue and partnership with all relevant stakeholders: other oncology specialists at national, European and international level; patient representatives and advocates; and, industry partners. ESTRO 39 aims at stimulating all stakeholders to enhance and shape radiotherapy for optimal health for each cancer patient.

The comprehensive scientific programme at ESTRO 39 offers state-of-the-art teaching lectures, symposia, debates on hot topics, as well as a range of educational activities such as pre-meeting courses, contouring workshops, and multidisciplinary tumour boards.

We put extra effort in optimising the programme format of ESTRO 39 by giving more room and visibility to contributions from abstract submissions. Sessions with highlights of proffered papers will take place in a plenary setting, offering maximum visibility to your work. Furthermore, we will aim to give more visibility to posters by increasing the number of posters that will be discussed offering you a platform to showcase your achievements. You are therefore strongly encouraged to submit an abstract by 23 October 2019 and become part of this prestigious event. Late breaking abstract submission will also be possible
as of early January 2020 and within the deadline of 15 January 2020.

The interdisciplinary component of the scientific programme, getting more space compared to the past editions, will include sessions on the following topics:
• How can AI improve contouring?
• Spatially fractionated radiation therapy (SFRT) - GRID therapy
• Cancer metabolism: implication for imaging, radiation response prediction and tumor radiosensitisation
• Cardiac radio-ablation
• FLASH: Radiotherapy with ultra-high dose rates
• Ultra-hypofractionation for localised prostate cancer
• Management of complex skin targets: which radiation technique
• MR-guided Radiotherapy: state of the art and future perspectives
• Preventing radiation-induced toxicity for the H&N region
• Dose accumulation and re-irradiation for breast and thorax
• How PROMS will change radiotherapy practice
• Targeting microenvironment in radiotherapy: where are we now?
• Redefining oligometastatic disease: incorporating advanced imaging into clinical trials
• Combined radiotherapy and immunotherapy in NSCLC

文章标题: 2021年第40届欧洲放射肿瘤学会大会/年会(ESTRO2021)
文章地址: http://www.laneva.com.cn/news/272825.html
Top